Anticholinergic

Extreme heat is particularly hard on older adults, and an aging population and climate change are putting ever more people at risk

Retrieved on: 
Wednesday, July 26, 2023

As researchers who study older adults’ health and climate change, we have found that two societal trends point to a potentially dire future: The population is getting older, and temperatures are rising.

Key Points: 
  • As researchers who study older adults’ health and climate change, we have found that two societal trends point to a potentially dire future: The population is getting older, and temperatures are rising.
  • Some of the country’s hottest states, including Arizona, are forecast to see dramatic growth in their older adult populations.
  • But heat isn’t just a problem in the South: Northern populations also face rising risks from extreme heat that many people aren’t accustomed to.

Why older adults face higher heat risks

    • Older adults don’t sweat or cool down as efficiently as younger people.
    • Heat stress can worsen underlying conditions like heart, lung and kidney disease, and extreme heat can trigger delirium.
    • For older adults with physical health problems, temperatures as low as 80 degrees F (26.7 C) – to say nothing of 110 degrees – can pose a grave danger.
    • Having to stay indoors all day to keep cool and enduring the stress of heat emergencies can make older adults depressed and isolated.

Drawn to high-risk regions

    • Retirees are often drawn to the South’s sunny skies, low taxes and costs of living and amenities, like golf courses, beaches, health care facilities and age 55+ residential communities tailored to their needs.
    • In Phoenix, the share of residents over age 65 is projected to rise from 10% of its 1.6 million residents today to roughly 17% by 2050.
    • At the same time that these populations are rising, the number of days people will need air conditioning is rising, too.

Northern regions are at risk, too

    • These regions – historically home to high shares of older adults – are projected to experience the steepest increases in heat exposure relative to temperatures historically experienced.
    • For older adults with health conditions, a night of restless sleep may make one more depressed and confused during waking hours.

What you can do about it

    • Be sensitive to symptoms like dizziness and call for medical attention as needed.
    • Deborah Carr receives funding from National Institutes of Aging and RRF Foundation for Aging.
    • Giacomo Falchetta receives funding from the Euro-Mediterranean Centre on Climate Change (CMCC).

Extreme heat is particularly hard on older adults – an aging population and climate change are putting ever more people at risk

Retrieved on: 
Tuesday, July 25, 2023

As researchers who study older adults’ health and climate change, we have found that two societal trends point to a potentially dire future: The population is getting older, and temperatures are rising.

Key Points: 
  • As researchers who study older adults’ health and climate change, we have found that two societal trends point to a potentially dire future: The population is getting older, and temperatures are rising.
  • Some of the country’s hottest states, including Arizona, are forecast to see dramatic growth in their older adult populations.
  • But heat isn’t just a problem in the South: Northern populations also face rising risks from extreme heat that many people there aren’t accustomed to.

Why older adults face higher heat risks

    • Older adults don’t sweat or cool down as efficiently as younger people.
    • Heat stress can worsen underlying conditions like heart, lung and kidney disease, and extreme heat can trigger delirium.
    • For older adults with physical health problems, temperatures as low as 80 degrees F (26.7 C) – to say nothing of 110 degrees – can pose a grave danger.
    • Having to stay indoors all day to keep cool and enduring the stress of heat emergencies can make older adults depressed and isolated.

Drawn to high-risk regions

    • Retirees are often drawn to the South’s sunny skies, low taxes and costs of living and amenities, like golf courses, beaches, health care facilities and age 55+ residential communities tailored to their needs.
    • In Phoenix, the share of residents over age 65 is projected to rise from 10% of its 1.6 million residents today to roughly 17% by 2050.
    • At the same time that these populations are rising, the number of days people will need air conditioning is rising, too.

Northern regions are at risk, too

    • These regions – historically home to high shares of older adults – are projected to experience the steepest increases in heat exposure relative to temperatures historically experienced.
    • For older adults with health conditions, a night of restless sleep may make one more depressed and confused during waking hours.

What you can do about it

    • Be sensitive to symptoms like dizziness and call for medical attention as needed.
    • Deborah Carr receives funding from National Institutes of Aging and RRF Foundation for Aging.
    • Giacomo Falchetta receives funding from the Euro-Mediterranean Centre on Climate Change (CMCC).

End Drug Shortages Alliance Releases Report for Drugs Impacted by Pharmaceutical Plant Closure

Retrieved on: 
Wednesday, March 15, 2023

The End Drug Shortages Alliance (EDSA) today released a report assessing the impact to the U.S. market caused by the recent closure of a drug manufacturer.

Key Points: 
  • The End Drug Shortages Alliance (EDSA) today released a report assessing the impact to the U.S. market caused by the recent closure of a drug manufacturer.
  • “Transparency regarding drug shortages is important to ensure patient care remains uninterrupted,” said Mittal Sutaria, senior vice president, Vizient pharmacy contract and program services and EDSA board member.
  • Clinicians and providers, to exercise a stewardship mindset and review purchasing and formulary status to determine conservation and mitigation strategies.
  • “Advance knowledge of supply disruptions is part of the transparency that the End Drug Shortages Alliance has advocated for since forming.

Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals

Retrieved on: 
Tuesday, May 3, 2022

BOULDER, Colo., May 03, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell” or “Company”), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, announced today that it has signed and closed a definitive asset purchase agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited (ASX: BOT) (“Botanix”), whereby Botanix has acquired the Company’s rights to sofpironium bromide, a retrometabolically-designed new chemical entity that belongs to a class of medications called anticholinergics. Sofpironium bromide gel, 15% is a potential best-in-class topical therapy that recently completed a U.S. Phase 3 pivotal clinical program for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating. Brickell was on track to submit a New Drug Application (“NDA”) to the U.S. FDA for sofpironium bromide gel, 15% in mid-2022.

Key Points: 
  • Brickell was on track to submit a New Drug Application (NDA) to the U.S. FDA for sofpironium bromide gel, 15% in mid-2022.
  • Under the terms of the agreement, Botanix has acquired from Brickell all assets primarily related to sofpironium bromide.
  • Botanix will be responsible for all further research, development, and commercialization of sofpironium bromide globally.
  • In connection with the sale of sofpironium bromide, Brickell and Botanix entered into a transition services agreement whereby Brickell will provide consulting services to Botanix through submission and potential approval of the U.S. NDA for sofpironium bromide gel, 15%.

Insights on the Asthma and COPD Drugs Global Market to 2030 - Key Players Include Novartis, Organon and Sanofi - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 3, 2022

The asthma and COPD drugs market was valued at $32988.7 million in 2020 and is projected to reach $52049.54 million by 2030, registering a CAGR of 4.64%% from 2021 to 2030.

Key Points: 
  • The asthma and COPD drugs market was valued at $32988.7 million in 2020 and is projected to reach $52049.54 million by 2030, registering a CAGR of 4.64%% from 2021 to 2030.
  • The increase in prevalence of asthma globally drives the growth of asthma and COPD drugs market.
  • In addition, increase in awareness about the respiratory diseases in people propels the growth of asthma and COPD drugs market.
  • Furthermore, initiatives taken by respective governments to treat and improve the lifestyle of asthma & COPD patients boosts market growth.

Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 9, 2021

BOULDER, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune, and other debilitating diseases, today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Key Points: 
  • Research and development expenses were $10.2million for the third quarter of 2021, compared to $1.3million for the third quarter of 2020.
  • Brickells net loss was $13.3million for the third quarter of 2021 compared to $4.3million for the third quarter of 2020.
  • A live webcast of the conference call can be accessed at http://public.viavid.com/index.php?id=146695 or through the Brickell Biotech website at https://ir.brickellbio.com.
  • In August 2021, Brickell acquired exclusive, worldwide rights to research, develop, and commercialize novel therapeutics generated from a proprietary DYRK1A inhibitor platform.

Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary Endpoints, from Both U.S. Phase 3 Pivotal Clinical Studies of Sofpironium Bromide Gel, 15% in Primary Axillary Hyperhidrosis Patients

Retrieved on: 
Thursday, October 7, 2021

BOULDER, Colo., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, today announced positive topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies, which evaluated sofpironium bromide gel, 15% as a once daily topical formulation in patients with primary axillary hyperhidrosis (excessive underarm sweating).

Key Points: 
  • Overall, 89% of patients who were randomized to sofpironium gel, 15% in the studies completed the full six weeks of treatment.
  • Five (2.9%) and nine (5.0%) subjects who received sofpironium bromide gel, 15%, discontinued the Cardigan I and II studies, respectively, due to a TEAE.
  • The dial-in number for the conference call is 1-877-705-6003 for domestic participants and 1-201-493-6725 for international participants, with Conference ID #13723931.
  • A live webcast of the conference call can be accessed here or through the Investors tab on the Brickell Biotech website at https://www.brickellbio.com .

Brickell Biotech Announces Final Patient Completed Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Retrieved on: 
Monday, August 16, 2021

BOULDER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that the final patient has completed the Phase 3 pivotal Cardigan II study, which is evaluating sofpironium bromide gel, 15% in patients with primary axillary (underarm) hyperhidrosis. The Company expects to announce topline results for the U.S. Phase 3 pivotal Cardigan I and Cardigan II studies concurrently in the fourth quarter of 2021. Pending the outcome of these studies, the Company expects to submit a New Drug Application (NDA) for sofpironium bromide gel, 15% to the U.S. FDA in mid-2022.

Key Points: 
  • Were excited to announce that all patients have now completed their final visits in the Cardigan I and Cardigan II studies of sofpironium bromide gel, 15% in patients with primary axillary hyperhidrosis.
  • Phase 3 clinical program for sofpironium bromide gel, 15% is comprised of two pivotal clinical studies, Cardigan I and Cardigan II.
  • Each study has enrolled approximately 350 subjects nine years of age and older with primary axillary hyperhidrosis.
  • The studies are multicenter, randomized, double-blinded, vehicle (placebo)-controlled studies evaluating the efficacy and safety of topically applied sofpironium bromide gel, 15%.

Brickell Biotech Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 12, 2021

BOULDER, Colo., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Key Points: 
  • Research and development expenses were $8.8million for the second quarter of 2021, compared to $2.7million for the second quarter of 2020.
  • General and administrative expenses were $2.9million for the second quarter of 2021, compared to $3.0million for the second quarter of 2020.
  • Total other income, net was $0.4million for the second quarter of 2021, compared to $7thousand for the second quarter of 2020.
  • Brickells net loss was $11.1million for the second quarter of 2021 compared to $5.1million for the second quarter of 2020.

HJF Receives Patent for Potential Treatment for Nerve Agent Exposure

Retrieved on: 
Tuesday, May 11, 2021

b"BETHESDA, Md., May 11, 2021 /PRNewswire/ --The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) received notice of allowance for a patent from the United States Patent Office (USPO) for a medical countermeasure to organophosphate (OP) nerve agent exposure.

Key Points: 
  • b"BETHESDA, Md., May 11, 2021 /PRNewswire/ --The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) received notice of allowance for a patent from the United States Patent Office (USPO) for a medical countermeasure to organophosphate (OP) nerve agent exposure.
  • The therapy was shown to be effective even with delayed use following nerve agent exposure.
  • Currently, treatment for OP exposure is with an anticholinergic agent administered immediately after exposure; thus, military personnel may receive kits containing atropine auto-injectors for use in the event of a nerve-gas attack.\nDr.
  • Importantly, this new combination therapy also extends the therapeutic window, as it is effective even when administered hours after OP exposure.